Our health care roundtable gathers the Motley Fool's top health care analysts to�discuss the sector's biggest stories in a free flowing and highly opinionated format.�
In this portion of the discussion, the Fool's health care team tackles the recent big pharma trend of spinning off whole divisions, like Abbott Labs' (NYSE: ABT ) plans for pharmaceutical-focused AbbVie. Would �conglomerate Johnson & Johnson (NYSE: JNJ ) benefit from shedding a little extra weight and spinning off a company or two?
In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. Offering everything from baby powder to biologics, critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand new premium report on Johnson & Johnson. To claim your copy simply click here now for instant access.
No comments:
Post a Comment